{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:53:57Z","timestamp":1792198437835,"version":"4.4.0"},"reference-count":79,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["#P30AG066444"],"award-info":[{"award-number":["#P30AG066444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AG003991"],"award-info":[{"award-number":["P01AG003991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AG026276"],"award-info":[{"award-number":["P01AG026276"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Kaohsiung J of Med Scie"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer disease (AD) and Alzheimer Disease and Related Dementias (AD\/ADRD) are growing public health challenges globally affecting millions of older adults, necessitating concerted efforts to advance our understanding and management of these conditions. AD is a progressive neurodegenerative disorder characterized pathologically by amyloid plaques and tau neurofibrillary tangles that are the primary cause of dementia in older individuals. Early and accurate diagnosis of AD dementia is crucial for effective intervention and treatment but has proven challenging to accomplish. Although testing for AD brain pathology with cerebrospinal fluid (CSF) or positron emission tomography (PET) has been available for over 2 decades, most patients never underwent this testing because of inaccessibility, high out\u2010of\u2010pocket costs, perceived risks, and the lack of AD\u2010specific treatments. However, in recent years, rapid progress has been made in developing blood biomarkers for AD\/ADRD. Consequently, blood biomarkers have emerged as promising tools for non\u2010invasive and cost\u2010effective diagnosis, prognosis, and monitoring of AD progression. This review presents the evolving landscape of blood biomarkers in AD\/ADRD and explores their potential applications in clinical practice for early detection, prognosis, and therapeutic interventions. It covers recent advances in blood biomarkers, including amyloid beta (A\u03b2) peptides, tau protein, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). It also discusses their diagnostic and prognostic utility while addressing associated challenges and limitations. Future research directions in this rapidly evolving field are also proposed.<\/jats:p>","DOI":"10.1002\/kjm2.12870","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T05:59:45Z","timestamp":1718690385000},"page":"692-698","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Advances in blood biomarkers for Alzheimer disease (\n                    <scp>AD<\/scp>\n                    ): A review"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-0338","authenticated-orcid":false,"given":"Araya Dimtsu","family":"Assfaw","sequence":"first","affiliation":[{"name":"Department of Neurology, Knight Alzheimer Disease Research Center (Knight ADRC) Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E","family":"Schindler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Knight Alzheimer Disease Research Center (Knight ADRC) Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Neurology, Knight Alzheimer Disease Research Center (Knight ADRC) Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"Global status report on the public health response to dementia [Internet].2021World Health Organization (WHO). Available from:https:\/\/www.who.int\/publications\/i\/item\/9789240033245"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(05)70225-5"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200310000-00010"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12328"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"issue":"3","key":"e_1_2_5_7_1","first-page":"822","article-title":"Fluid biomarkers in dementia diagnosis","volume":"28","author":"Schindler SE","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00335-x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020536"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69113-7"},{"issue":"4","key":"e_1_2_5_11_1","first-page":"569","article-title":"Blood biomarkers from research use to clinical practice: what must be done? A report from the EU\/US CTAD task force","volume":"9","author":"Angioni D","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12330"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2019-0735"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2005.06.003"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317513488910"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12314"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000851"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-230029"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01382-x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-020-00008-0"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.070428"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.05.017"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013211"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02869-z"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115094"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12422"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2003.tb00179.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.16.2094"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.07.021"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.05.016"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.SMJ.0000167699.56872.56"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0891988706291088"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2011.09.003"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2014.55.347"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.013"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12000"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0651"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.07.220"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043384772"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1385\/JMN:24:1:055"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-022-00269-x"},{"key":"e_1_2_5_44_1","unstructured":"US Food and Drug Administration.Amyvid (florbetapir F18 injection) [highlights of prescribing information].2012https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202008s000lbl.pdf"},{"key":"e_1_2_5_45_1","unstructured":"US Food and Drug Administration.Vizamyl (flutemetamol F18 injection) [highlights of prescribing information].2013https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203137s000lbl.pdf"},{"key":"e_1_2_5_46_1","unstructured":"US Food and Drug Administration.Neuraceq (florbetaben F18 injection) [highlights of prescribing information].2014https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204677s000lbl.pdf"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00451-6"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8392"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13764"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00403-3"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103911"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0481-z"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-019-0448-1"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01875-3"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01822-2"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1282"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044260"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.215"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003246"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200358"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.08.099"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2017.05.010"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25334"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052761"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13390"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooab052"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1267020"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00520-w"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01369-8"},{"key":"e_1_2_5_75_1","first-page":"585","article-title":"Downstream biomarker effects of gantenerumab or Solanezumab in dominantly inherited Alzheimer disease: the DIAN\u2010TU\u2010001 randomized clinical trial","volume":"29","author":"Wagemann O","year":"2024","journal-title":"JAMA Neurol"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12132"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02594-w"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-05542-4_2"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13101738"},{"issue":"3","key":"e_1_2_5_80_1","first-page":"306","article-title":"Platform trials to expedite drug development in Alzheimer's disease: a report from the EU\/US CTAD task force","volume":"8","author":"Aisen PS","year":"2021","journal-title":"J Prev Alzheimers Dis"}],"container-title":["The Kaohsiung Journal of Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/kjm2.12870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T07:57:34Z","timestamp":1722499054000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/kjm2.12870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/kjm2.12870"],"URL":"https:\/\/doi.org\/10.1002\/kjm2.12870","archive":["Portico"],"relation":{},"ISSN":["1607-551X","2410-8650"],"issn-type":[{"value":"1607-551X","type":"print"},{"value":"2410-8650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"2024-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}